Generation of two (2) lines of mice in which the ctcf gene is modified by crispr gene editing to contain either (1) an R448Q mutation; (2) a GRP>AAA mutation in A.A. 662-664. Please see attached slide…
Ended Purchase Order Awarded Last action
- Contract number
- 75N93023P01167
- Awardee
-
Leveragen Inc. UEI MBHPE8GND6R6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $60,000
Award facts
- Opportunity
-
- Immunization of Alpacas with HIV-1 Env Trimers to Develop Broadly Neutralizing Nanobodies Targeting CD4 Binding Site Pre-Solicitation · NOINIAID232182229 · Posted Aug 8, 2023
- Contract value 100% obligated
- $60,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 112990 All Other Animal Production
- PSC
- 8820 Live Animals, Not Raised For Food
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Worcester, MA 01605, USA
Award details come from SAM.gov/FPDS.
About this award
This firm fixed price purchase order, valued at $60,000, was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Leveragen Inc. of Worcester, Massachusetts. Under this contract, Leveragen will generate two lines of mice with specific CRISPR gene edits to the CTCF gene, containing either an R448Q mutation or a GRP>AAA mutation in amino acids 662-664. This work directly continues the solicitation to develop broadly neutralizing nanobodies targeting the CD4 binding site of HIV-1 through immunization of alpacas with HIV-1 Env trimers, by providing the genetically modified mice required for further study as described in the attached slide deck. Leveragen will deliver the mice lines over a one year period beginning in late August 2023.
Description
Generation of two (2) lines of mice in which the ctcf gene is modified by crispr gene editing to contain either (1) an R448Q mutation; (2) a GRP>AAA mutation in A.A. 662-664. Please see attached slide deck for design strategies. Complete service F
Quick answers
Who was awarded contract 75N93023P01167?
75N93023P01167 was awarded to Leveragen Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 30, 2023.
How much is contract 75N93023P01167 worth?
The government has obligated $60,000 on 75N93023P01167.
Was contract 75N93023P01167 competed?
The extent of competition for 75N93023P01167 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award